Key Developments: ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

8.25USD
27 Mar 2015
Change (% chg)

$0.27 (+3.38%)
Prev Close
$7.98
Open
$8.00
Day's High
$8.26
Day's Low
$7.98
Volume
333,781
Avg. Vol
426,383
52-wk High
$15.55
52-wk Low
$5.35

Search Stocks

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical announces business alliance with ImmunoGen
Monday, 23 Mar 2015 07:00pm EDT 

Takeda Pharmaceutical Co Ltd:Formed a business alliance of exclusive license of antibody-drug conjugate, which is owned by Takeda Pharmaceutical, with ImmunoGen Inc.  Full Article

ImmunoGen Inc reaffirms FY 2015 outlook
Friday, 30 Jan 2015 06:30am EST 

ImmunoGen Inc:Says its financial guidance remains unchanged from that issued in Oct. 2014.Expects FY 2015 revenues to be between $100 mln and $105 mln.Expects FY 2015 net loss to be between $60 mln and $65 mln.FY 2015 net profit of ($60) mln - Thomson Reuters I/B/E/S.  Full Article

ImmunoGen Inc reaffirms FY 2015 guidance
Friday, 24 Oct 2014 06:30am EDT 

ImmunoGen Inc:Says that its financial guidance remains unchanged from that issued in Aug.Expects FY 2015 revenues to be between $100 million and $105 million.Expects FY 2015 net loss to be between $60 million and $65 million.FY 2015 revenue of $101 million and net loss of $64 million - Thomson Reuters I/B/E/S.  Full Article

ImmunoGen Inc reaffirms FY 2015 revenue guidance - Conference Call
Monday, 8 Sep 2014 09:55am EDT 

ImmunoGen Inc:Says revenues for FY 2015 should be in the $100 million to $105 million range.  Full Article

ImmunoGen Inc gives FY 2015 guidance above analysts' estimates
Friday, 1 Aug 2014 06:30am EDT 

ImmunoGen Inc:Expects FY 2015 revenues to be between $100 mln and $105 mln.Expects FY 2015 net loss to be between $60 mln and $65 mln.FY 2015 revenue of $71 mln and net income of $(78) mln - Thomson Reuters I/B/E/S.  Full Article

ImmunoGen Inc announces preclinical findings for IMGN779
Monday, 16 Jun 2014 06:30am EDT 

ImmunoGen Inc:Disclosed for first time preclinical data for IMGN779.IMGN779 is a novel, CD33-targeting, DNA-alkylating ADC that is potential treatment for acute myeloid leukemia (AML).Despite good initial responses to existing therapies, many AML patients relapse, driving the need for new treatment options.IMGN779 is ADC designed to selectively target and kill AML cells, including leukemic stem cells, while sparing normal cells.IMGN779 utilizes DGN462, one of company's new DNA-acting payload agents.In preclinical findings reported at EHA, IMGN779 demonstrated potent, targeted activity against primary AML patient cells in vitro.IMGN779 can selectively kill leukemic cells (blasts) while sparing normal hematopoietic (blood) stem cells.IMGN779 was found to be highly active against human AML xenografts in vivo, demonstrating potent and targeted activity.IMGN779 was well tolerated without delayed toxicity in animal models.IMGN779 is on track to become the company's next wholly owned clinical-stage compound.ImmunoGen is preparing to submit the IMGN779 IND in mid-2015.  Full Article

ImmunoGen Inc lowers FY 2014 outlook
Friday, 25 Apr 2014 06:30am EDT 

ImmunoGen Inc:Expects FY 2014 revenues between $60-$64 mln, compared with previous guidance of between $71-$75 mln.Expects FY 2014 net loss to be between $71-$75 mln, compared with previous guidance of between $67-$71 mln.FY 2014 revenue of $76 mln - Thomson Reuters I/B/E/S.  Full Article

ImmunoGen Inc reaffirms FY 2014 guidance
Friday, 31 Jan 2014 06:30am EST 

ImmunoGen Inc:Sees fiscal 2014 revenues to be between $71 million and $75 million, unchanged from previous guidance.Sees fiscal 2014 net loss to be between $67 million and $71 million, unchanged from previous guidance.Fiscal 2014 revenue of $72 million - Thomson Reuters I/B/E/S.  Full Article

ImmunoGen Inc appoints David Johnston as chief financial officer
Monday, 30 Dec 2013 08:00am EST 

ImmunoGen Inc:Appoints David Johnston as executive vice president and chief financial officer, effective today.  Full Article

ImmunoGen Inc Announces Approval of Roche Holding AG's Kadcyla in European Union
Wednesday, 20 Nov 2013 01:10am EST 

ImmunoGen Inc announced that the European Commission has granted marketing approval for Kadcyla (trastuzumab emtansine; ado-trastuzumab emtansine in the US) in the European Union (EU). This event triggers a $5 million milestone payment to ImmunoGen. Kadcyla has been approved for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin (trastuzumab) and a taxane, separately or in combination. Patients should have either: (1) received prior therapy for locally advanced or metastatic disease or (2) developed disease recurrence during or within six months of completing adjuvant therapy. Kadcyla consists of Roche Holding AG's trastuzumab antibody with ImmunoGen`s DM1 cytotoxic agent attached using one of ImmunoGen's engineered linkers. Roche has global development and commercialization rights for Kadcyla; ImmunoGen is entitled to receive royalties on product sales as well as specified milestone payments.  Full Article

Search Stocks